Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.

Clinically, the nomogram model, which incorporates Gleason score and the risk score, could effectively predict BCRFS and potentially be utilized as a useful tool for the screening of BCRFS in PCa.